Full Press Release Details
PHILADELPHIA, May 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the acceptance of two abstracts for presentation at the American Society of Gene & Cell Therapy 24th Annual Meeting being held virtually, May 11-14, 2021. Accepted abstracts will highlight preclinical data from the Company’s Fabry and Pompe gene therapy programs, which Amicus is developing with the Gene Therapy Program of the Perelman School of Medicine at the University of Pennsylvania.
Digital Poster Session: Tuesday, May 11, 8:00 - 10:00 a.m. ET
Title: Post-Symptomatic Reversal of Muscle Pathology in a Model of Pompe Disease Using Gene Therapy
Session title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
Abstract number: 518
Presenter: Ali Ramezani, Ph.D., Senior Research Investigator, Project Lead, Translational Research, Gene Therapy Program, University of Pennsylvania
Title: Efficacy of Adeno-Associated Viruses Expressing an Engineered Alpha-Galactosidase A Transgene in a Mouse Model of Fabry Disease
Session title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
Abstract number: 519
Presenter: CJ (Chunjuan) Song, Ph.D., DABT, Research Director, Translational Research, Gene Therapy Program, University of Pennsylvania
The posters will be made available on the Amicus website following their respective presentations at the meeting.
For more information on the American Society of Gene & Cell Therapy 24th Annual Meeting, please visit https://annualmeeting.asgct.org/.
About Amicus Therapeutics
Sr. Director, Investor Relations
Head of Global Corporate Communications